Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GKIND002A
- Development stage
- Preclinical
- Lead developer
- China Resources Guokang
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
GKIND002A is a small molecule therapeutic candidate being developed by China Resources Guokang Pharmaceutical for the treatment of peptic ulcers associated with *Helicobacter pylori* (HP) infection. As of 2024, the asset is in the IND-enabling stage, specifically at the Clinical Trial Application (CTA) submission phase in China. The drug is designed to target *H. pylori*, a primary causative agent of chronic gastritis and peptic ulcer disease, although its specific molecular mechanism of action (such as inhibition of specific bacterial enzymes or cell wall synthesis) has not been publicly disclosed.
- Other names
- GKIND002AGKIND-002AGKIND 002A
Beyond the preview
Go deeper on GKIND002A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GKIND002A.